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ABSTRACT
Introduction: Cardiovascular disease (CVD) is a
common and serious complication of type 2
diabetes mellitus (T2DM) often linked to the
increased morbidity and mortality associated
with T2DM. Monitoring and treating risk
factors for CVD are important elements of
diabetes management. This review aims to
examine CV risk in people with relatively early
and mild diabetes who are at substantial risk of
CVD; it considers the impact of insulin therapy
on this risk by focusing on key studies in
patients with diabetes.
Methods: A literature search was carried out
using PubMed to identify key publications,
between 2008 and 2013, related to insulin and
its possible effect on CVD. This review examines
CV risk in diabetes and the impact of insulin
therapy on this risk.
Results: Studies have shown that treatment
with insulin glargine is associated with marked
improvement in the lipid profile of people with
T2DM. Intensive insulin therapy has been
shown to lower mortality rates in people with
diabetes following acute myocardial infarction
after 1 year. Retrospective data also indicate
that insulin reduces the risk of CVD events,
regardless of whether people had comorbidities
known to increase CV risk. The prospective
ORIGIN (Outcome Reduction with Initial
Glargine Intervention) trial found that
treatment with insulin glargine had a neutral
effect with regard to CV outcomes in people
with prediabetes or early diabetes, compared
with standard care.
Conclusions: Other ongoing, large-scale studies
of insulin therapy should provide further
insights into whether or not insulin therapy
can influence long-term CV outcomes.
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INTRODUCTION
Elevated cardiovascular (CV) risk is a serious
complication in people with type 2 diabetes
mellitus (T2DM), and it is often linked to
increased morbidity and mortality. Indeed,
approximately two-thirds of people with
T2DM die of heart disease or stroke [1, 2].
People with diabetes often have other risk
factors for cardiovascular disease (CVD),
including obesity, high blood pressure and
high lipid levels. Diabetes was once considered
a ‘risk equivalent’ of CVD (i.e., that it placed
people at the same risk of a cardiac event as
those who had already experienced one). The
measurement of glycated hemoglobin A1c
(HbA1c) levels in subjects with diabetes has
been shown to help predict the likelihood of
CVD occurring. While HbA1c remains an
important indicator, it is the development of
risk engines, in recent years, that have helped to
provide a more comprehensive and graded risk
of CV complications occurring in patients with
diabetes based on a summary of the patient’s
individual risk factors [3]. Such examples
include the United Kingdom Prospective
Diabetes Study (UKPDS) risk engine, Oxford
risk engine, a 5-year risk model developed by
the Swedish National Diabetes Register and the
American College of Cardiology/American
Heart Association guidelines on the assessment
of CV risk [4–6]. In a recent study, the
association between common indicators of
diabetes (postprandial glycemia, overall
hyperglycemia, glucose variability, and HbA1c
level) and CVD risk factors (lipids, high-
sensitivity C-reactive protein, and blood
pressure) was examined in people with type 1
diabetes mellitus (T1DM) and T2DM. Using
linear regression models, it was found that
HbA1c showed the strongest associations with
CVD risk [7]. Furthermore, in an observational,
registry-based study of people with T2DM, those
with tightly controlled baseline HbA1c levels
and blood pressure (median 6.5% and
130/80 mmHg, respectively) had considerably
decreased risks of CVD, myocardial infarction
(MI), coronary heart disease (CHD), and stroke
when followed for 6 years compared with
individuals who did not have tight control of
HbA1c levels and blood pressure [8]. A second,
similar observational study showed
progressively increasing risks of CHD, CVD,
and total mortality with higher HbA1c levels [9].
This trial showed that people with baseline
HbA1c levels of 6.0–6.9% (mean 6.5%) had a
20% lower relative risk of CHD and a 16% lower
risk of CVD than people with HbA1c levels of
7.0–7.9% (mean 7.5%) [9].
These observational studies demonstrate that
glycemic control is linked to CV risk in people
with T2DM and prospective clinical trials have
been undertaken that confirm this association.
It is therefore important that people with
diabetes receive care that provides both good
glycemic control and is optimized to deliver the
best CV outcomes possible [10]. Owing to their
varied mechanisms of action, different diabetes
therapies are likely to have different CV effects.
A review by Holden et al. [11] revealed that the
prevalence of insulin use in the UK has risen
considerably in the diabetes population and
that this is primarily due to the increase in
patients with T2DM using insulin, in
combination with oral agents, to achieve
glycemic control. A 7.5-fold increase was
reported in the total number of people with
T2DM using insulin in 1991 compared to 2010
(37,000 and 277,400 people, respectively) [11].
Changes in the management of T2DM have also
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occurred during this time and this has been
reflected in patterns of insulin use over this
period. In the USA, in 1997, 2.3 million people
with diabetes were on an insulin monotherapy
regimen compared to 1.1 million people on
insulin combination therapy. In 2010, the
number of people with diabetes on insulin
monotherapy and combination therapy was
2.8 million and 2.9 million, respectively [11].
Insulin therapy is considered to be the most
effective method of controlling blood glucose,
but its influence beyond glycemic control is not
widely appreciated. Insulin has been shown to
have potent anti-inflammatory effects, to
influence blood coagulation and to
significantly improve measures of endothelial
dysfunction. The aims of this review are to
examine CV risk in people with relatively early
and mild diabetes with substantial CV risk and
consider the impact of insulin therapy on this
risk, focusing on key studies in patients with
diabetes: the UKPDS [12, 13], the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) [14], the Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) [15], the
Veteran Affairs Diabetes Trial (VADT) [16], and
the Outcome Reduction with Initial Glargine
Intervention (ORIGIN) [17].
METHODS
A literature search was conducted using
PubMed to identify key publications between
2008 and 2013 that related to human studies of
insulin and its possible impact on CV outcomes
in people with T2DM. The search focused on
clinical trials, meta-analyses, and relevant sub-
studies of the trials included. Emphasis was
placed on combinations of the following words
as search terms: cardiovascular, CV; myocardial
infarction, MI; stroke; insulin; glargine;
detemir; NPH; aspart; lispro; glulisine. The
search was limited to articles in the English
language. The references of meta-analyses and
earlier review studies investigating similar
subject matter were also examined to find
earlier studies of particular importance and
relevance to be included in this review. The
analysis in this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
UKPDS
The UKPDS [12] investigated the effect of
intensive glycemic control with either
sulfonylurea or insulin compared with
conventional treatment in people with newly
diagnosed T2DM (Table 1). The primary
endpoints investigated were risk of diabetes-
related endpoints (sudden death, death from
hyperglycemia or hypoglycemia, fatal or non-
fatal MI, angina, heart failure, stroke, renal
failure, amputation (of at least one digit),
vitreous hemorrhage, retinopathy requiring
photocoagulation, blindness in one eye or
cataract extraction), diabetes-related death
(death from MI, stroke, peripheral vascular
disease, renal disease, hyperglycemia or
hypoglycemia, and sudden death), and all-
cause mortality over a median of 10 years. The
risk of single clinical endpoints, including MI,
stroke, and peripheral vascular disease, was also
investigated [12].
The use of intensive treatment targeting
fasting plasma glucose (FPG) \6 mmol/L
resulted in lower HbA1c levels after 10 years
(7.0% vs. 7.9%) compared with conventional
treatment (best achievable FPG on diet alone,
with drugs only added if there were
hyperglycemic symptoms or FPG [15 mmol/L)
[12]. There was a trend toward reduced risk for
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the three primary composite endpoints with
intensive control compared with conventional
treatment: 12% lower risk for any diabetes-
related endpoint (P = 0.029); 10% lower risk for
diabetes-related death (P = 0.34); and 6% lower
risk for all-cause mortality (P = 0.44). A 25% risk
reduction for microvascular outcomes was
observed with intensive treatment (P = 0.0099)
and this was the major contributor to the
reduction in risk of any diabetes-related
outcomes. No risk reduction for macrovascular
outcomes was observed during the 10-year
treatment period of the UKPDS; however,
there was a significant post-trial risk reduction
for MI of 15% with intensive insulin-based
therapy after a median follow-up of 16.8 years
[13].
The UKPDS transformed the treatment of
people with T2DM and led to the use of more
intensive glycemic control in everyday clinical
practice. As a result of this, three large clinical
trials were initiated to determine whether
intensive glycemic control had an impact on
CV outcomes. These three trials were:
ACCORD [14], ADVANCE [15], and VADT
[16] (Table 1).
ACCORD
The ACCORD trial compared the effect of
intensive (target HbA1c \6.0%) and standard
therapy (target HbA1c 7.0–7.9%) in 10,251
people with T2DM and either established CVD
or additional CV risk factors [14]. At the start of
the trial, both the intensive and conventional
treatment groups had poor glycemic control
(HbA1c 8.3 ± 1.1%) and, after 1 year, both
groups achieved stable HbA1c levels (6.4% and
7.5% in the intensive and conventional
treatment groups, respectively). The ACCORD
trial was terminated early, after 3.5 years’
follow-up, owing to an increased risk of death
in the intensive therapy arm [14]. Despite the
increased risk of CV and all-cause mortality
with intensive therapy, there was a trend
toward reduced risk for the primary endpoint
[combination of first occurrence of non-fatal MI
or non-fatal stroke or death from CV causes;
hazard ratio (HR) (95% CI) = 0.90 (0.87–1.04)].
The main cause of this reduced risk was a
significant reduction in the risk of non-fatal MI
with intensive treatment [HR (95% CI) = 0.76
(0.62–0.92); P = 0.004] [14]. This effect was only
observed after about 3 years and the authors
suggest that any benefits from intensive
glycemic control might take several years to
emerge [14]. There was a significant increase in
risk for hypoglycemia (P\0.001), as well as
increased risk of weight gain of more than 10 kg
(P\0.001) with intensive treatment, and it has
been suggested that these might both play a role
in the increased mortality associated with
intensive control.
Post hoc analyses were performed to
investigate whether hypoglycemia was
associated with this increased mortality. These
analyses found that, even though severe
hypoglycemia was associated with an
increased risk of death in both study arms, the
risk of death in people who experienced at least
one severe hypoglycemic episode was lower
with intensive control compared with
standard care [18]. Conversely, a small but
statistically significant inverse relationship
between the number of symptomatic and
unrecognized hypoglycemic episodes and the
risk of death was observed with intensive
control compared with standard care [19]. This
relationship was, however, of uncertain clinical
significance, suggesting that hypoglycemia was
not the main driver for the increased mortality
seen with intensive control [19].
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ADVANCE
The ADVANCE trial compared the effect of
standard glycemic control with intensive
glycemic control [use of gliclazide (modified
release) plus other drugs to target HbA1c B6.5%]
in 11,140 people with T2DM and either
established macro- or microvascular disease or
additional CV risk factors [15]. After 5 years,
HbA1c was lower with intensive control than
with standard care (6.53 ± 0.91% vs.
7.30 ± 1.26%). There was no reduction in the
risk of macrovascular events with intensive
control compared with standard care [HR (95%
CI) = 0.94 (0.84–1.06)]; however, there was a
significant reduction in the risk of major
microvascular events [HR (95% CI) = 0.86
(0.77–0.97); P = 0.01] [15]. An increased risk
for hypoglycemia and weight gain (0.7 kg
greater weight gain with intensive control vs.
standard care; P\0.001) was observed with
intensive treatment.
A post hoc analysis found that severe
hypoglycemia was associated with an
increased risk for a number of adverse
outcomes, including major macro- and
microvascular events and mortality [20]. The
authors of this analysis highlighted that, as
there was no relationship between the number
of severe hypoglycemic episodes and adverse
event occurrence, it was possible that severe
hypoglycemia only acted as a marker of
vulnerability [20]. This suggests that even
though hypoglycemia may be a contributor to
adverse outcomes, there are likely other
explanations for the inconsistent outcomes of
these trials.
VADT
The VADT compared the effects of intensive
(targeting a 1.5% decrease in HbA1c) and
standard care on CV outcomes in 1,791 people
with poorly controlled T2DM [21]. There was a
decrease in HbA1c observed at 3 months; by
6 months, this had stabilized, with HbA1c levels
being maintained in both groups for the
remainder of the trial. There was a greater
decrease in HbA1c with intensive treatment
and a 1.5% difference in HbA1c levels was
maintained from 6 months to the trial end
[21]. No significant difference was observed
between the intensive and standard care
groups in the primary endpoint, which
combined macrovascular and microvascular
events and death from CV causes, and there
was no difference between groups in death from
any cause. There was a greater incidence of
adverse events in the intensive therapy group
compared with the standard care group (24.1%
vs. 17.6%, respectively). The most frequent
adverse event was hypoglycemia, which
occurred significantly more frequently with
intensive therapy (P\0.001) [21].
Meta-analyses of ACCORD, ADVANCE,
VADT, and UKPDS
The ACCORD, ADVANCE and VADT studies
failed to demonstrate a reduction in CV
mortality with more intensive glycemic
control [14–16, 21]. There was a decrease in
microvascular events in the ACCORD study, but
no effect on macrovascular outcomes,
confirming the results of the 10-year UKPDS
[12, 14]. No vascular benefit from intensive
control was observed in ADVANCE or VADT
[15, 21]. Nonetheless, a meta-analysis including
the 27,049 participants from the
aforementioned trials (ACCORD, ADVANCE,
UKPDS, and VADT) found a 9% risk reduction
in major CV events (CV death or non-fatal MI or
non-fatal stroke) with intensive therapy
compared with standard therapy [HR (95%
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CI) = 0.91 (0.84–0.99); Fig. 1] [21]. This
reduction was primarily due to a 15%
reduction in the risk of MI (fatal or non-fatal)
with intensive therapy [HR (95% CI) = 0.85
(0.76–0.94)] [21]. Other meta-analyses
investigating the effect of intensive glycemic
control on CV outcomes have been performed,
including UKPDS, ADVANCE, ACCORD, and
VADT, as well as additional studies [22–26].
These analyses reach different conclusions
depending on the trials included; however,
overall, there appears to be evidence that
intensive glycemic control provides limited CV
benefits.
Subanalyses of ACCORD, ADVANCE,
VADT, and UKPDS
Owing to the conflicting results from UKPDS,
ACCORD, ADVANCE, and VADT, subgroup
analyses have been performed to identify
whether any subgroups experienced a benefit,
which is masked by the presence of people who
do not experience this benefit in the overall
Fig. 1 The effects of intensive versus standard glycemic
control on a major cardiovascular events (CV death or non-
fatal MI or non-fatal stroke) and b MI (fatal or non-fatal)
[21]. ACCORD Action to Control Cardiovascular Risk in
Diabetes, ADVANCE Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR Controlled
Evaluation, CI conﬁdence interval, CV cardiovascular,
HbA1c glycated hemoglobin, MI myocardial infarction,
UKPDS United Kingdom Prospective Diabetes Study,
VADT Veteran Affairs Diabetes Trial
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population. Prespecified subgroup analyses of
the ACCORD trial found that people receiving
intensive therapy who had not experienced a
previous CV event and those with HbA1c B8%
may have experienced fewer fatal or non-fatal
CV events than those receiving standard care
(P = 0.04 and 0.03, respectively) [14]. Subgroup
analysis of the ADVANCE trial found that the
results of intensive control were consistent for
all subgroups [15].
The lack of agreement between UKPDS and
the other trials (ACCORD, ADVANCE, and
VADT) in terms of a reduction in CV risk, with
intensive glycemic control in people with
T2DM, is likely due to very different follow-up
times between them, with only the UKPDS
having a follow-up of more than 10 years
compared with the shorter follow-up in the
other studies [27]. Nevertheless, these studies
and subanalyses of them highlighted that
intensive glycemic control is not suitable for
everyone, and the need for diabetes care to be
personalized. This patient-centered approach to
diabetes care was described by the American
Diabetes Association (ADA)/European
Association for the Study of Diabetes (EASD)
in a joint consensus statement on the
management of hyperglycemia [28]. This
statement highlights that glycemic targets
should be selected based on patient
characteristics; for example, glycemic targets
for frail elderly patients should be less strict
than for younger patients owing to the
increased risk of hypoglycemia with intensive
control.
In addition to reducing blood glucose,
therapies also have different effects as a result
of their differing mechanisms of action. It has
been suggested that the lack of agreement
between trials investigating the effect of
intensive glycemic control on CV outcomes
may have been due to the use of different drugs
and combinations of drugs [29–32].
Consequently, the therapies used either had a
neutral effect on CV risk or produced adverse
CV effects—for example, by inducing weight
gain. It is, therefore, important that the CV
effects of different therapies are determined to
enable prescribers to choose the most effective
treatments according to the needs of each
individual.
INSULIN AND CV OUTCOMES
Retrospective Studies
Retrospective studies investigating the impact
of insulin on CV outcomes have produced
inconsistent results. A retrospective study
published in 2004 by Nichols et al. [33]
comparing 8,231 people with T2DM, with a
matched cohort of people without diabetes,
found that people with T2DM were 2.5-times
more likely to develop congestive heart failure
(CHF) than those without. When they
compared the incidence of CHF with the
therapies being used, they found that the
addition of insulin increased the risk of CHF
by 2.33 and 2.66 times compared with the
addition of sulfonylurea or metformin,
respectively [34]. A retrospective study by
Margolis et al. [35] in 2008 examining 63,579
people with T2DM over 40 years of age during
clinical practice also found that insulin may
have a negative impact on CV outcomes. This
study found that insulin use was associated with
a 1.2-times greater risk of MI, with the risk
increasing with longer use. These studies
suggest that insulin has a negative impact on
CV outcomes. However, a study published in
2012 by Hall et al. [36] investigating treatment
intensification in 14,904 people with poorly
controlled T2DM found that initiating insulin
did not increase the incidence of macro- or
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microvascular events compared with the
addition of an oral antidiabetic drug (OAD). In
another study, Roumie et al. [37] compared
time to CV events in a cohort of 178,000
metformin-treated patients who received
either add-on insulin therapy or a sulfonylurea
from 2001 to 2008. The results showed that the
addition of insulin or a sulfonylurea to patients
receiving metformin was associated with an
increased risk of a composite of non-fatal CV
outcomes and all-cause mortality; the authors
suggest that further study is warranted to better
understand these associations. A retrospective
analysis by Saleh et al. [38] found that, after a
mean follow-up of 4.14 years, mortality rates for
patients with T2DM who had undergone
coronary angiography were highest in the
insulin-treated, and insulin in combination
with OAD groups compared to the other
groups (diet only, OAD alone). Norhammar
et al. [39] reviewed long-term mortality data
from the Swedish Coronary Angiography and
Angioplasty Registry in patients with and
without T2DM after a first percutaneous
coronary intervention (PCI). The authors
concluded that not only was long-term
mortality higher in patients with T2DM
following a first PCI compared to patients
without diabetes but that the mortality gap
between the two groups increased with follow-
up time. In another retrospective study, Raebel
et al. [40] examined antihyperglycemic
medication intensification treatment of
patients with incident diabetes. The findings
showed that insulin use was rarely considered as
the first treatment intensification therapy for
patients with diabetes on OADs. The authors
surmise that this may be because some
clinicians and patients are reluctant to initiate
insulin due to the choice of OADs available;
consequently, patient’s and clinician’s attitudes
should be addressed accordingly. The
conflicting results from retrospective studies
have led to several prospective studies being
undertaken to investigate whether insulin does
have an effect on CV outcomes.
Prospective Studies
The Translating Research Into Action for
Diabetes prospective observational study
followed 8,334 people with T2DM over 8 years
[41]. In this population, it was observed that the
use of insulin monotherapy was associated with
1.24-times greater risk for all-cause mortality
compared with OAD monotherapy [42].
However, combination therapy with OAD plus
insulin was not associated with increased risk for
overall mortality compared with the use of OADs
alone. When CV and non-CV mortality were
considered separately, the use of insulin was seen
to be a risk factor for CV mortality but not non-
CV mortality [42]. This highlights that the use of
insulin is correlated with CV outcomes. This
study did not investigate the different
components of insulin therapy and it is possible
that, as long-acting insulin analogs
predominantly target FPG and rapid-acting
analogs target postprandial glucose (PPG), they
will have different CV effects. Another
prospective observational study by Mellbin
et al. [43] found that while there was no
significant difference in mortality between
insulin, metformin and sulfonylureas, a higher
risk of non-fatal MI or stroke was observed in
patients with T2DM receiving insulin. According
to the study findings, after a median follow-up
interval of 2.1 years, a protective effect was seen
with metformin and an indeterminate response
was observed with sulfonylureas.
Rapid-acting Insulin Analogs
The Nippon Ultra-Rapid Insulin and Diabetic
Complication Evaluation study was a 5-year,
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open-label, randomized controlled trial that
compared CV outcome in 325 Japanese people
with T2DM intensively treated with either
regular human insulin or insulin aspart [44].
The primary endpoint of this study was a
composite CV endpoint, including MI, angina
pectoris, cerebral infarct/transient ischemic
attack, coronary artery bypass graft, or PCI. A
43% reduction in the incidence of the primary
composite endpoint was observed in people
treated with insulin aspart compared with those
treated with regular human insulin [6.4% (12.8/
1,000/year) vs. 11.3% (22.2/1,000/year),
respectively; P\0.02] [44]. There was no
significant difference between groups for
HbA1c or FPG levels; however, 90-min PPG
levels were significantly lower in the insulin
aspart-treated group (142 ± 58 mg/dL vs.
226 ± 48 mg/dL; P\0.02). This suggests that
PPG levels could significantly contribute to CV
risk.
The association between postprandial
hyperglycemia and CV risk has been
investigated in other studies. The Diabetes
Intervention Study found that, over 11 years,
1-h post-breakfast blood glucose, but not FPG,
was associated with a higher risk of MI and
death in 1,139 newly diagnosed people with
T2DM aged 30–55 years old [45]. The 14-year
follow-up to the San Luigi Gonzago Diabetes
Study that investigated 505 people with T2DM
found that both HbA1c and 2-h PPG levels were
predictors of both CV events and all-cause
mortality [46]. The DECODE study, which
included 22,514 people with diabetes, also
demonstrated that 2-h PPG was a better
predictor of both all-cause and CV mortality
compared with FPG [47].
The studies highlight that PPG plays an
important role in CV risk and it has been
suggested that this could occur because wide
glycemic fluctuations induce oxidative stress
that damages the vasculature [48]. However,
guidelines recommend that insulin is initiated
as a basal insulin analog to provide control of
FPG and it is, therefore, important to
understand whether it has any CV effects [28].
Long-acting Insulin Analogs
The ORIGIN study was designed in an attempt
to determine whether insulin therapy can
influence long-term CV outcomes [17].
ORIGIN was a 6-year, randomized, open-label,
controlled, international, interventional study.
The trial investigated whether insulin glargine,
targeting normal FPG versus standard
approaches to glycemia management, could
reduce CV morbidity and/or mortality in
people with early T2DM or prediabetes at
high risk of CV events [17]. The ORIGIN
study was the first large trial designed to
specifically assess the impact of insulin on CV
outcomes. Unlike ACCORD, ADVANCE, and
VADT, ORIGIN studied patients with
prediabetes or early T2DM; therefore, glucose
control was more easily achieved and
maintained [10–12]. The study also compared
omega-3 polyunsaturated fatty acids (PUFAs)
versus placebo in reducing CV events in the
same population. A total of 12,537 people
(C50 years of age, mean age 63.5 years, 35%
women) with evidence for either established
CVD or a high-grade CVD risk factor, and with
either prediabetes or early T2DM, were enrolled
across 40 countries. At randomization, 82%
had established diabetes, 6% had newly
diagnosed diabetes and 12% had impaired
fasting glucose (IFG) or impaired glucose
tolerance (IGT), mean duration of diabetes
was 5.4 years. Mean FPG was 7.3 mmol/L and
median HbA1c level at baseline was 6.4%
(interquartile range 5.8–7.2%). Approximately
two-thirds of participants had a previous
history of CVD.
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The two co-primary outcomes for insulin
glargine versus standard care comparison were
composites of major CV events. These were: (1)
CV death, non-fatal MI or non-fatal stroke and
(2) the same three events plus a
revascularization procedure or hospitalization
for heart failure. Additional outcomes of
interest included total mortality (all causes),
risk of diabetic microvascular outcomes and
progression of IGT or IFG to T2DM. CV death
was the primary outcome for the omega-3 PUFA
comparison.
The final analysis, after a median follow-up
of 6.2 years, included [99% of participants and
found that the incidence of both co-primary
endpoints, or any of their component parts, did
not differ significantly between insulin glargine
and standard care groups [HR: 1.02 (95% CI
0.94–1.11; P = 0.63) and 1.04 (95% CI
0.97–1.11; P = 0.27) for co-primary endpoints
1 and 2, respectively; Fig. 2]. There was also no
difference in mortality [HR: 0.98 (95% CI
0.90–1.08); P = 0.70] or microvascular events
[HR: 0.97 (95% CI 0.90–1.05); P = 0.43] between
treatment arms. HbA1c was lower with insulin
glargine compared with standard of care, with a
between-group difference of 0.3% (6.2% and
6.5% with glargine and standard of care,
respectively). Of those with diabetes at
baseline 60% and 45% of the insulin glargine
and standard care groups, respectively, had
HbA1c \6.5% at 5 years [50]. Post hoc analysis
found that people receiving insulin glargine
were more likely to maintain HbA1c\6.5% than
Fig. 2 Risk of cardiovascular outcomes in the ORIGIN
trial—analysis for hazard ratio of insulin glargine versus
standard care [17]. CI conﬁdence interval, ORIGIN
outcome reduction with initial insulin glargine. Reprinted
from N Engl J Med, ORIGIN trial investigators, basal
insulin and cardiovascular and other outcomes in dysgly-
cemia Volume No. 367, 319–328. Copyright  (2013)
Massachusetts Medical Society. Reprinted with permission
from Massachusetts Medical Society [17]
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people receiving standard care [OR: 2.98 (95%
CI 2.67–3.32); P\0.001] [50].
During the study, participants in the insulin
glargine group experienced modest weight gain
(median change: ?1.6 vs. -0.5 kg for insulin
glargine and standard care, respectively) and
more episodes of hypoglycemia (rate of severe
hypoglycemia 0.01 vs. 0.0031 per person-year
for insulin glargine and standard care,
respectively) than the standard care group,
both of which have been linked to increased
CV outcomes in epidemiological studies. In a
post hoc analysis, severe hypoglycemia was
found to be associated with a greater risk for
co-primary outcome, mortality, CV death, and
arrhythmic death [51]. Nonetheless, the relative
risk of CV outcomes with hypoglycemia was
lower with insulin glargine than with standard
care, highlighting that insulin glargine itself
does not affect CV outcomes.
There was no overall increase in CV
outcomes in this study despite increased
hypoglycemia and weight gain with insulin
glargine treatment, suggesting either that
these adverse effects do not cause these
outcomes or that any potential harm was
offset by a treatment benefit. This beneficial
effect is unlikely to be associated with
concomitant treatment, as more metformin
was used in the standard of care than the
insulin glargine arm, suggesting that any
treatment benefit was related to insulin
glargine itself.
Owing to its design, the ORIGIN study
looked specifically at the CV outcomes of
insulin glargine treatment and not at the
effect of improved glycemic control, and
found no association between insulin glargine
and CV outcomes. This suggests that the CV
benefits reported in previous small-scale or
long-term follow-up studies might be related
to the metabolic effects of treatment, rather
than the insulin itself. Alternatively, it could be
that ORIGIN was not of sufficient duration to
show a modulation of CV outcomes that may
take more than a decade to manifest.
The near normal median HbA1c level at
baseline in the ORIGIN study population
helped to minimize any bias in the findings
against insulin. Despite the benefits of early
insulin initiation, patients are frequently placed
on insulin therapy much later in the disease
course of diabetes when the burden of illness is
higher and HbA1c levels are uncontrolled on
OADs. In these instances, patients receiving
insulin therapy may be viewed as a proxy for
‘worse disease’ and could therefore confound
any results against insulin in favor of other
therapies. The objective of the ORIGIN trial was
not to demonstrate whether insulin improved
glycemic control in patients with near normal
HbA1c levels but to determine the effect of
insulin, if any, on CV outcomes in patients with
early and mild diabetes.
A recently published sub-study of the
ORIGIN trial used continuous glucose
monitoring in a subset of subjects to examine
glycemic variability, PPG effects and
hypoglycemia after 2 years of treatment.
Findings indicate that treatment to target FPG
\5.3 mmol/L with insulin glargine was not
associated with a modestly increased risk of
hypoglycemia. Furthermore, strict control of
FPG was effective in controlling PPG excursions
[49].
Even though several large prospective
clinical trials have been carried out, and
demonstrate that insulin glargine has a neutral
effect on CV outcomes, there are a number of
important questions that remain unanswered.
Further analyses from the ORIGIN extension
study [Outcome Reduction with an Initial
Glargine Intervention and Legacy Effect
(ORIGINALE)] and the Cardiovascular Risk
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Evaluation in people with type 2 Diabetes on
Insulin Therapy (CREDIT) study, will provide
further information on the long-term CV and
general safety profiles of insulin therapy. The
results for insulin glargine need to be expanded
to cover other long-acting insulin analogs, and
the extent to which FPG contributes to CV risk
needs to be determined. In addition, if insulin is
found to have effects on CV risk beyond
glycemic control in these trials, the
mechanism by which insulin could be
providing additional CV protection would
need to be determined.
DISCUSSION
Diabetes is an independent risk factor for CV
events; however, it is often associated with a
number of comorbidities including obesity.
These comorbidities can themselves be risk
factors for CV events, making it difficult to
determine the impact of diabetes treatment on
CV risk. However, long-term prospective studies
have demonstrated that maintaining glycemic
control at the levels recommended by the ADA
and EASD (HbA1c \7%) results in a clinically
relevant decrease in CV risk [28].
The optimization of glycemic control,
should, therefore, be emphasized for people
with diabetes to reduce the risk of CV outcomes.
However, only 35.6–50.0% of people in the USA
reach glycemic targets of HbA1c \7% as
suggested by the ADA and EASD [28, 52]. This
is, therefore, increasing the risk of CV events in
a large proportion of people with diabetes. This
poor control could result from a number of
factors, including clinical inertia and poor
adherence to treatment or blood glucose
monitoring; therefore, it is important that the
reason for poor glycemic control is determined,
enabling the treatment to be individualized,
thus ensuring that it has maximal impact. This
could include patient education programs, the
use of insulin pen devices rather than vial and
syringe, and patient-led titration of insulin. The
results of the ORIGIN study demonstrate that
insulin glargine has no effect on CV outcomes,
and the improved outcomes that result from
optimal glycemic control suggest that
treatment should be intensified when glycemic
control worsens to maintain treatment benefits,
including the use of insulin as recommended by
the ADA/EASD consensus statement [28].
The ADA/EASD recommends that people
with T2DM receive a multifaceted therapy
program comprising various CV risk reduction
strategies, such as lipid- and blood-pressure-
lowering therapies, as appropriate [53, 54]. The
STENO-2 study demonstrated that the use of
intensive multifactorial treatment had
sustained beneficial effects on the incidence of
vascular complications, as well as rates of all-
cause and CV-related mortality [54]. Despite the
evidence of the effectiveness of combination
therapy, 40–88% of people with diabetes
worldwide are undertreated [55]. This is clearly
an unmet need in the treatment of T2DM.
Effective glycemic control, targeting
normoglycemia, is essential for people with
diabetes as it reduces the risk of CV
complications and mortality. The importance
of optimal glycemic control was underscored by
the UKPDS, which transformed the way in
which diabetes is treated. Subsequently, a
series of large prospective clinical trials were
performed (ACCORD, ADVANCE, and VADT)
that investigated the impact of intensive
glycemic control on CV outcomes. Although
the trials produced inconsistent results and a
definite benefit of intensive control could not
be determined, meta-analyses including these
trials suggest that there is a benefit, in particular
a reduction in the incidence of non-fatal MI.
Indeed, sub-studies of the ACCORD and
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ADVANCE trials demonstrated that intensive
glycemic control is not beneficial for everybody
and highlighted the need for personalized care
in T2DM. In addition, it was important to
determine which treatments would be
beneficial for specific subpopulations of people
with diabetes. The ORIGIN trial, the first large-
scale trial specifically investigating the impact
of insulin on CV outcomes, demonstrated that
insulin glargine was CV neutral in people with
IGT and early diabetes and that the beneficial
effects seen were predominantly a result of
improved glycemic control. However, the
possibility that treatment with insulin glargine
has additional CV effects beyond glycemic
control has not been ruled out.
While there are studies that have suggested
a possible increase in CV risk associated with
insulin use in patients with T2DM, it is
important to highlight that despite the
benefits of early insulin use, insulin therapy is
often reserved for patients with advanced and
long-standing diabetes that is uncontrolled
with OADs. Such a population, as a course of
their uncontrolled disease, would be expected
to be at increased risk of microvascular disease,
making it difficult to determine whether the
increased risk is attributed to insulin therapy or
the study population itself. In addition, the
lack of consistent, and often contradictory,
findings regarding the effect of insulin on CV
outcomes in both retrospective and prospective
studies highlights the need for more rigorous
research to be carried out in the form of a RCT.
A key limitation of these studies, acknowledged
by the authors themselves, is the short
duration of follow-up and it is clear that
further research needs to be done in this area
with a longer duration of follow-up to truly
ascertain the extent of the relationship
between insulin treatment and CV outcomes
in the long term.
CONCLUSION
Optimal glycemic control in people with T2DM
should be determined on a case-by-case basis
dependent on each individual’s characteristics.
In people with CV risk factors, optimal glycemic
control should be supplemented by a
multifactorial approach targeting known CV
risk factors (including hypertension,
hypercholesterolemia, and hyperlipidemia). An
individualized approach targeting both
glycemic control and CV risk factors should
enable the best outcome to be obtained in every
person with T2DM.
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